Fred Cohen, PhD MD, is a managing director at Texas Pacific Group Ventures, where he initiated their investment efforts in the life sciences. He retains a professorship of cellular and molecular pharmacology at the University of California, San Francisco (UCSF). Dr. Cohen also serves as a member of the boards of GenomicHealth, XDx, Kemia, CardioDx, Anaborex, and Matrix Pharmaceuticals. He is also a member of the investment committee of the board of Quintiles Transnational. Mr. Cohen received his MD from Stanford, his PhD in molecular biophysics from Oxford as a Rhodes Scholar, and his bachelor’s degree from Yale University in molecular biophysics and biochemistry. Dr. Cohen has been a member of the faculty of UCSF since 1986, and is best known for his work on protein structure and the conformational basis of prion disease. He is a member of the Institute of Medicine of the National Academy of Sciences.


print email
Price Data
NASDAQROKA